Expression of Sox2 in human ovarian epithelial carcinoma
Expression of Sox2 in human ovarian epithelial carcinoma
复制标题
Sox2在人卵巢上皮癌中的表达
DOI：
10.1007/s00432-010-0867-y
复制
发表时间：
2011-01-01
影响因子：
3.6
通讯作者：
Chen, Huaizeng
中科院分区：
文献类型：
--
作者：
Ye, Feng;Li, Yanli;Chen, Huaizeng
这项研究的目的是研究在一系列良性，边缘和恶性卵巢肿瘤中Sox2（转录因子）的表达，并评估SOX2表达水平是否与卵巢上皮癌中的临床病理学特征相关。 43种正常卵巢上皮的Sox2，284种浆液上皮病变和164种粘液上皮病变评估其临床病理学相关性。免疫组织化学结果表明，Sox2表达的正比逐渐从良性和边缘性卵巢肿瘤逐渐增加。 55.81％的正常卵巢上皮菌类似于65％的浆液性和粘液性囊肿瘤，类似于70％的边界浆液和粘液性囊肿瘤，分别与91％的浆液性和粘液性囊这型囊腺癌表达了SOX2。但是，浆液性肿瘤或粘液性肿瘤患者的SOX2表达与CA125的年龄和水平之间没有显着相关性。在浆液和粘液性膀胱癌样品中都鉴定了SOX2表达水平与FIGO阶段或病理阶段之间的正相关。卵巢肿瘤的恶性转化。
ObjectivesThe aim of this study was to investigate the expression of Sox2, a transcription factor, in a series of benign, borderline, and malignant ovarian tumors and to evaluate whether Sox2 expression levels correlate with clinicopathological characteristics in ovarian epithelial carcinoma.MethodsThis study investigated immunohistochemical expressions of Sox2 in 43 species of normal ovarian epithelia, 284 species of serous epithelial lesions, and 164 species of mucinous epithelial lesions to assess their clinicopathological relevance.ResultsImmunohistochemical results showed that the positive ratio of Sox2 expression gradually increased from benign and borderline to malignant ovarian tumors; 55.81% of normal ovarian epithelia, ~65% of serous and mucinous cystadenoma, ~70% of borderline serous and mucinous cystadenoma, and ~91% of serous and mucinous cystadenocarcinoma expressed Sox2, respectively. However, there was no significant correlation between Sox2 expression and the age and level of CA125 in patients with either serous or mucinous tumors. Positive correlations between Sox2 expression levels and FIGO stage or pathological stage were identified in both serous and mucinous cystadenocarcinoma samples.ConclusionThe expression level of Sox2 in human ovarian tumors was directly proportional to their degree of malignancy, implying that Sox2 overexpression may be closely related to the malignant transformation of ovarian tumors.